Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug combination
Biotech
Merck briefly posts trial plan for PD-1xVEGF and TROP2 ADC combo
A brief, now-deleted clinical trial listing on Merck’s website revealed its plans to test the bispecific, coded MK-2010, alongside sac-TMT.
Angus Liu
Jul 29, 2026 3:00pm
Sierra buys AstraZeneca cancer drug to pair with ex-Gilead asset
Aug 5, 2021 4:05pm
New insight into a struggling AZ cancer drug could expand its use
May 17, 2019 10:27am
Bristol-Myers, Compugen ally to test checkpoint combinations
Oct 11, 2018 9:10am
Bristol-Myers posts early data on IDO1-checkpoint inhibitor combo
Nov 10, 2017 9:28am
Celgene bags Beigene PD-1 drug for $263M up front
Jul 6, 2017 4:22am
